L1 Makes Immunological Progress by Expanding Its Relations by Kadmon, Guni et al.
Developmental Immunology, 1998, Vol. 6, pp. 205-213
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1998 OPA (Overseas Publishers Association)
N.V. Published by license under the
Harwood Academic Publishers imprint,
part of the Gordon and Breach Publishing Group
Printed in Malaysia
Minireview
L1 Makes Immunological Progress by Expanding Its
Relations
GUNI KADMONa, ANTHONY M.P. MONTGOMERY and PETER ALTEVOGTa*
aDepartment of Cellular Immunology 0710, German Cancer Research Centre, Im Neuenheimer Feld 280, D-69120 Heidelberg,
Germany; bDepartment of Immunology, The Scripps Research Institute,, 10666 North Torrey Pines Rd., La Jolla, California 92037
(Received 15 August 1996; In final form 12 April 1997)
The cell-adhesion molecule L1 was originally described in the nervous system. It has recently
been detected in CD4 T lymphocytes, peripheral B lymphocytes, and granulocytes in the human
immune system and in similar leucocyte types in the murine immune system. L mediates neural
recognition by Ca+z, Mg+2-independent homophilic binding. In the human and murine immune
systems, L1 binds to the "classical" vitronectin receptor, ceV/33, and fibronectin receptor, ce5/31,
respectively, and abstains from homophilic binding. Homophilic L1 binding probably involves
antiparallel alignment of several interactive domains. Integrin binding is mediated by a short
segment of immunoglobulinlike domain 6, which includes two RGD repeats in rodent L1 and
one RGD motif in human L1. L1 is modulated in activated leucocytes in vitro in parallel to
i-selectin, and diverse cell types release intact L in vivo and in vitro. Released L1 can bind to
laminin and adheres to the extracellular matrix of sciatic nerve, M21 melanoma, and possibly
spleen and other tissues. It can support integrin-dependent cell migration and preliminary data
implicate it in tumor development and transnodal lymphocyte migration.
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INTRODUCTION
The development of a functional cellular immune
system and effective immune response depends on
selective leucocyte trafficking to, from, and within
organs of the immune system as well as to variable
but specific addresses such as inflammatory sites.
*Corresponding author.
Correct leucocyte trafficking is mediated by contact-
dependent interactions between leucocytes and post-
capillary endothelial cells, glandular stroma cells, and
extracellular matrices. These interactions require
multiple-adhesion mechanisms that can recognize
appropriate targets and be modulated by the cell
during recognition events. Intensive investigations of
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TABLE L1-Expressing Cell Types of Haematopoietic Lineages in Man and Mouse
Human Murine
CD4 peripheral blood T lymphocytes
--<20% CD31 peripheral blood T lymphocytes
CD19 peripheral blood B lymphocytes
CD14 peripheral blood monocytes
Tumors: haematopoietic tumor lines including monocytic’---
U937, HL60; T lymphomaJMOLT-3,
Jurkat; B lymphoma--Raji. Neuroblastomas; Melanoma--M21;
small cell lung tuimors.
Mature thymocytes
Approx. 20% of CD3 splenic T lymphocytes
B220 splenic B lymphocytes
GR1 bone marrow granulocytes
Tumors: several haematopoietic tumor lines, neural tumors.
leucocyte extravasation have produced ample
information on the mechanisms mediating leucocyte-
endothelial recognition (for extensive reviews, see
Butcher, 1991; Imhof and Dunon, 1995). There is,
however, little information on the adhesion mecha-
nisms that mediate leucocyte migration through and
beyond the endothelial wall, through lymph glands
and inflamed tissues.
During the last year, the cell-adhesion molecule L
has emerged as an important candidate for mediating
such processes. L1 is primarily expressed by neural
and blood cells involved in targeted migration and is
at present the only known cell-adhesion molecule that
is abundant in both nervous and immune systems. Its
importance in human ontogenesis is underlined by the
severity of neurological disorders associated with
mutations in the L1 gene. These include hydrocepha-
lus and mental retardation and have recently been
united under the acronym CRASH syndromes (Fran-
sen et al., 1995). Associated manifestations in the
immune system remain to be defined.
In the nervous system, L1 is predominantly
expressed by neuronal subsets and Schwann cells. It
mediates neuronal adhesion, axonal navigation and
fasciculation, axon-Schwann cell recognition, and
possibly granule-cell migration. In the immune
system, L1 is expressed by neutrophils and lympho-
cyte subsets (Table I). Its function(s) in the immune
system is not certain, but preliminary studies using
tumor lines, T and B lymphoblasts suggest that L1
may be involved in both leucocyte-leucocyte and
leucocyte-endothelial cell interactions.
L1 is a transmembranal glycoprotein with apparent
molecular weight of 190-230 kD. Its protein backbone
contains six immunoglobulin domains (domains Ig
1-6), five fibronectin type III domains (domains
FNml-5), and two known alternatively spliced mini-
exons, exons 2 and 27 (Figure 1A). Murine and rat L1
share 97% identical amino acids (Miura et al., 1991),
human and murine L1 approximately 87% (Kobaya-
shi et al., 1991), and the related molecules, chicken
NgCAM and Drosophila neuroglian have 43% (Bur-
goon et al., 1991) and 27% (Bieber et al., 1989) amino
acid identity to rodent L1, respectively. The glycosy-
lation pattern of L1 is variable and accounts for
20-35% of its apparent molecular weight. L1 variably
expresses the carbohydrate epitopes HNK-1 and L3
(Fig. 1B). The HNK-1 epitope is involved in L1
binding to laminin (Hall et al., 1993) and ligand
binding to P- and L-selectin (Needham and Schnaar,
1993; Sammar et al., 1994), whereas the L3 glycan
has been implicated in L1-NCAM cohesion in
neurones (Horstkorte et al., 1993). The expression of
the HNK-1 and L3 epitopes by L1 in blood cells has
not been studied.
L1 LIGANDS
The functional vicissitude ofL has been attributed to
its recently discovered diversity of binding mecha-
nisms (Table II). In rodents and man, L1 can bind to
at least three counterreceptors with distinct cation
requirements. The major L1 ligand for L1-expressing
murine leucocytes and lymphoma ESb-MP cells
appears to be the "classical" fibronectin receptor,
ce5fll integrin (Ruppert et al., 1995). Ll-ce5fil
binding requires Ca+z, Mg+2 and preactivation ofL1 IN THE IMMUNE SYSTEM 207
A. Protein Backbone of L1
NH2
differentially YEGHH spliced
Igl
Ig3
ETA
extracellular
iii membrane
differentially
intracellular spliced
ankyrin?
spectrin?
Ig5
Ig6
FN
trypsin
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FIGURE Schematic representation of L1. (A) L1 is a transmembranal glycoprotein with six immunoglobulinlike (Ig1-6) and five
fibronectin type III-like (FNInl-5) domains in its extracellular segment. Two proteolytic sites (broken lines) generate characteristic fragments
(vertical double arrows) in vivo and in vitro. Alternative splicing of two microexons generates several isoforms. In neurones, the intracellular
tail can possibly be anchored to spectrin via a neural isoform of ankyrin. The positions of potential a5/31 (ETA, RGDG, RGDS, NGR), a4/31
(LDV), and FGF receptor-homology sequences (APY, APYW), basic box (+), cystein residues outside (*) and inside (S) Ig domains, and
conserved tyrosine (Y) and tryptophan (W) residues in FNI domains are indicated. Clouded areas denote putative interactive segments
mediating homophilic binding. (B). The glycan structure of HNK-1- and L3-immunoreactive glycolipids. L1 variably expresses both
epitopes. HNK-1- and L3-immunoreactive glycolipids inhibit L1 binding to laminin and NCAM, respectively. HNK-l-immunoreactive
glycolipids also bind to ,-and I-selectins.208 GUNI KADMON et al.
TABLE II Homophilic Binding and Integrin Binding by L1 in Different Cell Types Analyzed by Direct Binding and Antibody Perturbation
Studies
Species Probe cells or beads Llexpression Examined cell interaction:aggregation or adhesion Bindingmechanism
Mouse Neurones Yes
Neuroblastoma N2A cells Yes
Neuroblastoma N2A cells Yes
Microbeads coated with N2A L1 Yes
Microbeads coated with N2A L1 Yes
Microbeads coated with N2A L1 Yes
Activated thymocytes Yes
ESb-MP cells (nonactivated) Yes
ESb-MP cells (activated) Yes
Bone marrow cells Yes
Man Melanoma M21 cells Yes
Melanoma M21 cells Yes
J558L cells transfected with L1 gene Yes
from M21 cells
J558L cells transfected with L1 gene Yes
from M21 cells
Lymphoblastic leukemia MED-B No
Adhesion to immobilized L1
Short-term homotypic aggregation
Long-term homotypic aggregation
Homotypic aggregation
Adhesion to thrombocytes (L1-)
Adhesion to bEnd3 endothelioma (L1-)
Adhesion to immobilized L1
Short-term homotypic aggregation
Short-term homotypic aggregation
Adhesion to thrombocytes (L1-)
Adhesion to immobilized human & rat L1
Adhesion to heat-denatured L1
Adhesion to immobilized L1
Adhesion to immobilized heat-denatured L1
Adhesion to immobilized human & murine L1
L1-Ll+Ll-other?
L1-L1
Ll-c5/31
L1-L1
Ll-c5/31
Ll-unknownLl-cV?
c5/31-L1
None
Ll-c5/31
Ll-oz5/31+Ll-other?
cV/33-L
cV/33-L
L1-L1
None
aV/33-L1
c5/31 via CD24 antibodies, by Mn+2 cations, or by
phorbolesters. In human cells of haematopoietic
lineages (Ebeling et al., 1996) and melanoma M21
cells (Montgomery et al., 1996), L1 strongly binds to
cV/33 and weakly to c5/31. The binding between L1
and oV/33 requires Ca+2 and Mg+2 but no prior
activation of the cells, although Mn+2 may enhance
the binding.
In the nervous system, L1 mediates neuronal
recognition by temperature- and cation-independent
homophilic binding (Lemmon et al., 1989). It is at
present not certain that neuronal L1 recognizes
additional ligands. Binding between neuronal L1 and
integrins has to our knowledge not been examined
under conditions that support integrin-L interactions.
However, purified L1 from murine neuroblastoma
N2A cells binds murine c5/31 and serves as a good
substrate for c5/31-mediated leucocyte adhesion in
the presence of Mn+2 in vitro (Ruppert et al., 1995).
Purified L1 from rat pheochromocytoma PC12 cells
(NILE) interacts with human cV/33 and possibly with
o5/31 (Montgomery et al., 1996). There are at present
no indications that L1 binds to mammalian homo-
logues of the chicken neuronal adhesion molecules
axonin-1 or Fll, the chondroitin sulphate proteo-
glycan neurocan, or the presumptive astrocytic
ligand(s) that is recognized by the chicken homologue
of L1, NgCAM (for a review, see Brtimmendorf and
Rathjen, 1993).
BINDING MECHANISMS OF L1
Homophilic Binding
Holm et al. (1995) have reported that microbeads
coated with intact L1 or with fusion proteins derived
from L1 domains Ig3-4 or FNnI3-5 strongly adhere to
substrate-immobilized L1. Microbeads coated with
fusion proteins derived from other short segments of
L1 or from longer segments that include these
domains underwent homotypic aggregation but
weaker or no adhesion to substrate-immobilized L1.
These observations appear to indicate that mutual
attraction among parallel domains of L1 could
facilitate L1 clustering on the cell surface, but trans
binding between L1 molecules may primarily involve
domains Ig3-4 and FNnI2-4 (Figure 2A). Systematic
analysis of the homophilic binding mechanism of L1
is still wanting. However, the data are consistent with
the proposed model for the homophilic binding
mechanisms of carcinoembryonic antigen (CEA;
Zhou et al., 1993) and platelet-endothelial cell-L1 IN THE IMMUNE SYSTEM 209
adhesion molecule (PECAM-1, CD3 l; Fawcett et al.,
1995). Like L1, CEA and CD31 belong to the
immunoglobulin supergene family and function as
Ca+2-independent cell-adhesion molecules. Homo-
philic CEA binding involves double reciprocal inter-
actions between the amino terminal and an internal
domain. Homophilic CD31 binding is primarily
mediated by domains 2, 3, 5, 6, but requires the
presence of all six domains. It has therefore been
suggested that stable homophilic binding is mediated
by antiparallel alignment of apposing molecules and
correct interdigitation of corresponding "high-affin-
ity" domains (Fig. 2A).
Heterophilic Binding to aVfl3 and a5/l
lntegrins
The major integrin-binding site of L1 lies in a
segment of domain Ig6 that includes the consensus
integrin-binding motif arginine-glycine-aspartate
(RGD; Fig. 2B and Fig. 2C). The adhesion of human
melanoma M21 cells to substrate-immobilized L1
depends on ozV expression and can be inhibited by
antibodies to cVfl3. It can also be prevented by
RGDG DVDG mutation in domain Ig6 of
substrate-adsorbed human L1 (Montgomery et al.,
1996). Moreover, the synthetic peptide
CWRGDGRDLQELGDSDKYFIEDGRLV derived
A
CD31
/NH
OOH
L1
B C D
murine L1, Ig6
GDGDLQIDKYFIEDGKLVTKS
rodent otV133? ot511 .?--’
" " rat L1, Ig6
IAGDRDLQ6DKYFIEDGLVIKS
huma aV3 +?+
IRGDDL EGDSDKYF IEVI S
Chicken NgCAM, FNIII3-4 __
PFSEPIAFETPEGVPGPPEELRV
rodent IH2
RGD " 6
Arg Gly Asp
(R) (G) (D)
DGR
(inverse II II]X
%
RGD
FIGURE 2 Presumptive binding mechanisms of L1. (A) Model for homophilic binding by CD31 and L1. Binding occurs between
interdigitated high-affinity domains (clouded regions) and requires correct antiparallel alignment of the intact molecules. (B) Presumptive
differential cVfi3- and c5fll-binding RGD motifs (boxed) in domain Ig6 of rodent and human L1. The homologous integrin-binding
peptides (single-letter notation) of rodent and human L1 and the nonhomologous RGD-containing segment of chicken NgCAM are shown.
(Boldface type) nonconserved residues. (Solid closed arrows) probable binding based on experimental evidence. (Broken closed arrows)
possible, but unverified binding. (Broken open arrows) nonconserved segments that possibly influence selective binding. (C) Schematic
model of domain Ig6 of L1. B-strands, disulphide bridge (S--S), and putative positions of RGD sequences are marked. Modified from
Williams (1987) by alignment with C2-set domains with known crystal structure. (D) Wire-frame model of the RGD loop required for Mill,
a2/31, and possibly c5/31 binding. Atom positions (heavy dots) in the RGD residues are shown. Acidic (-) and basic (+) side chains are
denoted by clouded shading. Adopted from Haas and Plow, 1994.210 GUNI KADMON et al.
from domain Ig6 ofhuman L predominantly binds to
cV/33 and supports the adhesion of cV/33-expressing
MED-B 1 cells but not c5/31-expressing Nalm-6 cells
(Ebeling et al., 1996). On the other hand, the synthetic
peptide CWRGDGRDLQERGDSDK derived from
domain Ig6 of murine L1 binds to o5/31, inhibits the
homotypic aggregation of murine lymphoma ESb-MP
cells, and supports c5/31-dependent adhesion of
murine peripheral thymocytes (Ruppert et al., 1995).
By amino acid sequence comparisons between
domain Ig6 of L1 and immunoglobulinlike domains
with known crystal structure, domain Ig6 of L1 most
closely resembles domain Ig2 of VCAM-1. It poten-
tially has a C2-set immunoglobulin fold (Fig. 2C)
with a short C’ strand and particularly elongated C’-E
loop. Rodent and human L 1 contain a conserved RGD
motif (RGDS; Fig. 2B) in the putative C-C’ loop. A
second RGD motif (RGDS; Fig. 2B) is expressed by
rodent L1 in the putative C’-E loop. However,
crystallographic analysis has not been performed, and
it cannot be excluded that both RGD motifs are
expressed on the same /3 loop (C-C’ or C-D). In
human L1, arginine to leucine change disrupts the
RGDS motif in the C’-E loop, whereas a lysine to
arginine change generates an "inverse" RGD (DGR)
motif at a different pogition, presumably on the same
/3 loop (Fig. 2C).
Mechanisms of Selective Integrin Binding
Since L1 is expressed by similar neuronal and
leucocyte subsets in mouse and man, the existence of
variable RGD sites in the otherwise highly conserved
molecule may reflect evolutionary adaptation of L to
binding functionally analogous integrins in different
species. The tripeptidyl RGD is expressed by most
integrin-binding matrix proteins and serves as the
main binding site for most integrin-substrate adhesion
molecules. However, different integrin dimers bind to
different RGD-expressing proteins, indicating that the
molecular context is a determinant factor in selective
RGD recognition (for reviews, see Ruoslahti, 1988;
Haas and Plow, 1994). RGD recognition by c1/31 and
c2/31 depends on RGD presentation in a flexible
conformation at the apex of a type II/3 loop with the
basic and acidic side chains of arginine and aspartate
pointing away from one another (Fig. 2D). A5/31
recognizes cyclic RGD-containing peptides, suggest-
ing similar conformational constraints, whereas cV/33
binds both to cyclic and linear RGD-containing
peptides (for a review, see Haas and Plow, 1994).
A5/31 strongly binds to murine (Ruppert et al., 1995)
but not human (Ebeling et al., 1996) L1. Therefore,
c5/31 possibly recognizes the fibronectinlike motif
RGDS of rodent L1 (Fig. 2B) that is missing in human
L1. AV/33 appears to bind to the conserved RGDG
site of L1 (Fig. 2B), since M21 cell adhesion to
human L1 is abolished by mutation of this motif
(Montgomery et al., 1996), and human cV/33 medi-
ates cell binding to human, rat (Montgomery et al.,
1996), and murine L1. However, binding of ozV/33 to
L1 has so far not been detected in murine cells. It is
therefore likely that species-specific differences in the
binding properties of oV/33 and possibly
codetermine the choice ofL ligand. It is at present an
open issue whether amino acid changes to the
carboxyl terminal to the RGD motifs of L1 (Fig. 2B)
are also important to selective integrin-L1 binding.
In addition to conformational constraints on RGD
presentation, conjoint non-RGD binding sites in the
ligand may also contribute to selective ligand recogni-
tion by RGD-binding integrins. Binding of cV
integrin(s) to collagen is enhanced in the presence of
short noncollagen RGD peptides, indicating that RGD
recognition activates cryptic collagen-binding sites in
cV integrins (Agrez et al., 1991). Binding of c5/31 to
the RGD motif in domain FNn10 ("cell-binding
domain") of fibronectin is imperative to stable contact
between c5/31 and matrix-embedded fibronectin. Yet,
the affinity of c5/31 to fibronectin is strongly reduced
by mutations in domains FNm8 and FNm9 of
fibronectin (Obara et al., 1988; Aota et al., 1991),
suggesting that additional non-RGD integrin-recogni-
tion sites are also important. Interestingly, L1 shares
with domains FNIn8 and FNm9 of fibronectin several
non-RGD peptide sequences that have been impli-
cated in c5/31 binding (Fig. 1). Preliminary studies
from our laboratory indicate that the synthetic cyclo-
heptapeptide *RRETAWA*, resembling one of those
sites, interferes with Ll-c5/31 binding through actionL1 IN THE IMMUNE SYSTEM 211
on a non-RGD site ofL 1. However, additional studies
will be required to determine the significance of this
observation and whether L1 domains other than
domain Ig6 indeed participate in regulating the
integrin-binding potential of L1.
antibody 324 modulates pp60 c-dependent phos-
phorylation in neurones (Atashi et al., 1992).
LI RELEASE AND INTERACTION WITH
THE EXTRACELLULAR MATRIX
Possible Roles of Homophilic and Integrin
Binding in Ll-dependent Adhesion, Migration,
and Signal Transduction
L1 joins a growing number of cellular receptors for
"classical" matrix-binding integrins (for a review, see
Imhof and Dunon, 1995). Among these, CD31 is of
particular interest since L1 and CD31 appear to have
similar homophilic binding mechanisms (Fig. 2A) and
high affinity for ceV/33 (Piali et al., 1995; Mon-
tgomery et al., 1996) but are expressed by mutually
exclusive lymphocyte subsets (Ebeling et al., 1996).
The functional significance of these dual binding
mechanisms is not clear. However, it seems possible
that homophilic L1 binding primarily mediates cell-
cell recognition and stimulation of FGF receptor-
mediated signal transduction, whereas Ll-integrin
binding may support cellular locomotion. Ll-trans-
fected J558L cells that adhere to immobilized L1 by
homophilic binding undergo very limited movement
on substrate L 1. Conversely, L1-expressing M21 cells
interact with L1 via ceV/33 and exhibit pronounced
ceV/33-dependent haptotactic movement on substrate
L1 (Montgomery et al., 1996). In addition, mono-
clonal L1 antibody 324 that specifically inhibits L1-
integrin interactions does not perturb the short-term
aggregation of murine cerebellar neurones and neuro-
blastoma N2A cells (Rathjen and Schachner, 1984).
But it inhibits the migration of granule-cell neurones
(Lindner et al., 1983) and neurite elongation (Fischer
et al., 1986) in cerebellar explants from postnatal
mice. Moreover, homophilic L1 binding activates
FGF receptor-dependent signal transduction in rat
neurones, but probably not nonreceptor-type tyrosine
kinases (Doherty et al., 1995). However, neurite
extension by murine cerebellar neurones on immobil-
ized L1 is specifically abolished by homozygous src
deletion (Ignelzi et al., 1994), and L cross-linking by
Several types of neurones release increased amounts
of L1 in response to nerve growth factor in vitro
(Richter-Landsberg et al., 1984). Melanoma M21
cells spontaneously release L1 at an average rate of
approximately 104 molecules/cell/hour (Montgomery
et al., 1996), and lymphocytes downregulate L1
expression upon activation in vitro and in vivo (Hubbe
et al., 1993). Stimulation of neutrophils with the
phorbolester PMA leads to rapid loss of L1 from the
cell surface with remarkably similar kinetics to the
shedding of i-selectin. L-selectin shedding has
recently been shown to depend on an MMPl-like
metalloendoprotease (Preece et al., 1996). Whether a
similar mechanism also applies to L1 remains to be
examined. Released L1 can be detected in association
with the extracellular matrix of murine sciatic nerve
(Martini and Schachner, 1986), and within intratumor
laminin strands of human melanoma M21 (Mon-
tgomery et al., 1986). Selective binding between
purified L1 and laminin has been demonstrated (Hall
et al., 1993), but the physiological function of matrix-
embedded L1 is still uncertain. Conceivably, matrix-
embedded L1 gradients may locally promote targeted
cell migration as a substrate for integrin adhesion.
Recent experiments using recombinant L1 have
shown that L1 indeed can support integrin-mediated
cell migration (Duzcmal et al., 1997). The possibility
that released L1 may promote intratumor angiogene-
sis by interaction with ceV integrins of sprouting
vessels can also be considered.
CONCLUSIONS
The cell-adhesion molecule L1 serves both as a cell-
adhesion molecule and as a matrix-embedded sub-
strate for cell migration. In both functions, L1 may
undergo homophilic interaction or bind to "classical"212 GUNI KADMON et al.
integrin-matrix receptors. Dual homophilic and integ-.
rin binding has also been reported for the nonneural
recognition molecules CD31 and E-cadherin. Homo-
philic binding has primarily been associated with
early recognition events. Binding between homophilic
cell-adhesion molecules and integrins appears to
stabilize cell connections and promote cell motility.
This information implies that the major difference
between cell-cell and cell-matrix interactions pertain
to early recognition and choice of contact. But the
mechanisms mediating long-term adhesion and
migration on cellular and matrix substrates may be
related.
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